MONTREAL, QUEBEC--(Marketwire - December 10, 2007) - Thallion Pharmaceuticals Inc. (TSX: TLN) today announced changes to its Board of Directors. Michael Kurman, M.D., an independent consultant to the pharmaceutical, biotechnology and health care industries, will be joining the Company as a new Board member, bringing 25 years of experience in oncology and anticancer drug development to Thallion. Dr. Sylvie Gregoire has resigned from Thallion’s Board of Directors in order to better fulfill her recently assumed professional commitments.
